In vivo SCID-beige xenograft model for DLBCL (RL). (A) Pharmacokinetic (PK) modeling of AT-101 after a single administration by oral gavage. AT-101 was administered at a 35 mg/kg or a 200 mg/kg; the AT-101 peak plasma concentration was observed after 30 minutes of administration of the drug in both the dose levels, with the 200 mg/kg group showing a plasma average concentration almost 4 times greater than the 35 mg/kg group (7.88 μM and 27.78 μM respectively). After 24 hours, AT-101 was still detectable in plasma with average concentrations of 0.49 μM for the 35 mg/kg group and 0.39 μM for the 200 mg/kg group. (B) In vivo activity of single AT-101 as a function of schedule. The 35 mg/kg per day for 14 days showed a statistically significant shrinkage of tumor volume compared to controls (P=.008); P values are shown; P values for each treatment group compared to control. All significance testing was done at the P less than .05 level. N equals 5 in each group.